Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies

doi:10.2174/1871520617666170103095527

	Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
	Guan, Haixing 1; Du, Yongli 1; Han, Weiwei 1; Shen, Jingkang 2; Li, Qunyi 3
刊名	ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
	2017
卷号	17 期号:5 页码:646-657
关键词	Anti-cancer agents cell cycle clinical trials cyclin-dependent kinases 4 selective inhibitors structure activity relationship (SAR)
ISSN号	1871-5206
DOI	10.2174/1871520617666170103095527
文献子类	Review
英文摘要	Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4 pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4 inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism of CDK4 inhibitors, the structure activity relationships(SARs) of the selective CDK4 inhibitors and the latest developments of the selective CDK4 inhibitors in clinical trials.
资助项目	National Natural Science Foundation of China[81202389] ; National Natural Science Foundation of China[81302853]
WOS关键词	SQUAMOUS-CELL CARCINOMAS ; CRYSTAL-STRUCTURE ; CDK INHIBITORS ; BREAST-CANCER ; CHEMICAL-CONSTITUENTS ; STRUCTURAL BASIS ; LIBRARY DESIGN ; DISCOVERY ; COMPLEX ; POTENT
WOS研究方向	Oncology ; Pharmacology & Pharmacy
语种	英语
出版者	BENTHAM SCIENCE PUBL LTD
WOS记录号	WOS:000403217100002
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/275712]
专题	药物化学研究室中科院受体结构与功能重点实验室新药研究国家重点实验室
通讯作者	Du, Yongli; Shen, Jingkang
作者单位	1.Qilu Univ Technol, Sch Chem & Pharmaceut Engn, 3501 Daxue Rd, Jinan 250353, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China; 3.Fudan Univ, Huashan Hosp, Clin Pharm Lab, 12 Wu Lu Mu Qi M Rd, Shanghai 200040, Peoples R China
推荐引用方式 GB/T 7714	Guan, Haixing,Du, Yongli,Han, Weiwei,et al. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies[J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY,2017,17(5):646-657.
APA	Guan, Haixing,Du, Yongli,Han, Weiwei,Shen, Jingkang,&Li, Qunyi.(2017).Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY,17(5),646-657.
MLA	Guan, Haixing,et al."Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies".ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 17.5(2017):646-657.